- Chronic kidney disease (CKD) is an independent predictor of major adverse cardiac events (MACE) at 5 years after implantation of an everolimus-eluting stent (EES; Xience V and/or Promus).
- EES implantation was effective and safe; rates of ischemia-driven target lesion revascularization (ID-TLR) and stent thrombosis (ST) were similar vs non-CKD patients.
Why this matters
- Limited data exist on safety and efficacy of second-generation drug-eluting stents in patients with preexisting CKD.
- Tokyo-MD PCI observational, multicenter study subanalysis, comparing outcomes for patients with CKD (n=316) and without (n=1424) after EES implantation.
- MACE defined as a composite of death, nonfatal myocardial infarction (MI), ID-TLR, and ST.
- Funding: None disclosed.
- Mean and median follow-up were 1391±557 and 1769 (interquartile range, 1012-1800) days, respectively.
- Patients with CKD had significantly higher 5-year rates of all-cause death (20.1% vs 8.2%; P<.001 cardiac death vs p=".007)," mace stroke and major bleeding>
- 5-year rates were similar with/without CKD for nonfatal MI (2.9% vs 3.3%; P=.68), ID-TLR (4.9% vs 3.7%; P=.26), and ST (0.5% vs 1.0%; P=.20).
- In multivariate analysis, CKD was tied to a 22% increased risk for MACE (HR=1.22; P=.01).
- Retrospective design.
- Nonstratified CKD.